Sun Pharmaceutical Industries will announce its financial results for the first quarter ended June 30, 2026, on July 31, 2026. The company has scheduled an earnings call to discuss the quarter's performance and address questions from investors and analysts, providing a detailed outlook on operations.

Earnings Call Details

The board of Sun Pharmaceutical Industries will review the results for the quarter ending June 30, 2026. Following the announcement, the company will conduct an hour-long conference call at 6:30 PM IST on July 31, 2026. Senior management will participate in the discussion to address queries regarding the financial performance.

Participants are required to pre-register via the provided link to avoid wait times and dial in five to ten minutes before the scheduled start. The operator will provide instructions for asking questions during the call. An audio webcast will also be available, with details to be announced on the company website. A transcript of the conference call will be published online post-event.

Eligible consumers and third-party payers who purchased certain generic drugs in the United States between May 1, 2009, and December 31, 2019, can now file claims to receive a share of $533 million in class action settlements. A federal court has granted final approval for the settlements, allowing Settlement Class Members to submit claim forms to recover overpayments allegedly caused by antitrust violations. The settlements involve Sun Pharmaceutical , Sandoz Inc., Apotex Corp., and Heritage Pharmaceuticals Inc., among others, in the lawsuit In re Generic Pharmaceuticals Antitrust Litigation.

The lawsuit alleges that generic manufacturers violated federal and state antitrust laws, consumer protection statutes, and common law, causing End-Payers (EPPs) to pay inflated prices. The Settling Defendants deny any wrongdoing, and the litigation continues against Non-Settling Defendants. Four EPP Settlement Classes have been certified, one for each settlement, covering Consumers and Third-Party Payers such as insurers or employers with self-funded plans. The settlements exclude Indiana, Ohio, and certain entity types.

Settlement Breakdown

The total settlement fund of $533 million comprises contributions from multiple manufacturers to resolve consumer and Third-Party Payer claims. The following table details the amounts paid by each settling entity:

After deducting notice and administration costs, attorney's fees, and litigation expenses, the remaining funds will be distributed proportionally to valid claimants. Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A., Inc. are collectively referred to as Sun/Taro in the settlement agreement.

How to File a Claim

To receive a payment, eligible class members must submit a claim form with supporting documentation. Claims can be filed online at the EPP Settlement Website or via a paper form postmarked by the deadline. The deadline for submission is November 9, 2026. Claimants do not need to sign up with a claims recovery firm or pay an additional law firm to participate.

Payment amounts depend on the total number of valid claims received and the claimant's documented spending on the Named Generic Drugs during the specified period. Failure to submit a claim form by the deadline will result in the forfeiture of any settlement benefits. Detailed information on the specific drugs included, class definitions, and claim procedures is available on the settlement website.